Medicine & Life Sciences
Survival
100%
Drug Therapy
95%
Adenocarcinoma
70%
Neoplasms
69%
Neoplasm Metastasis
59%
Colorectal Neoplasms
59%
Neoadjuvant Therapy
57%
Therapeutics
55%
Liver
50%
Rectal Neoplasms
50%
Recurrence
49%
Progression-Free Survival
45%
United States Food and Drug Administration
45%
Pharmaceutical Preparations
44%
Biomarkers
42%
Hepatocellular Carcinoma
39%
Irinotecan
38%
Cholangiocarcinoma
38%
Clinical Trials
36%
Biliary Tract Neoplasms
35%
Stomach Neoplasms
33%
Hepatitis C
33%
Esophageal Neoplasms
33%
Fluorouracil
33%
Hepatectomy
32%
Gastrointestinal Neoplasms
29%
Immunotherapy
26%
Safety-net Providers
26%
Systematic Reviews
26%
Pancreatic Neoplasms
26%
Hepacivirus
26%
N-(3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl)-3-(2-((((1,1-dimethylethyl)amino)carbonyl)amino)-3,3-dimethyl-1-oxobutyl)-6,6-dimethyl-3-azabicyclo(3.1.0)hexan-2-carboxamide
25%
Cross-Sectional Studies
25%
Gastro-enteropancreatic neuroendocrine tumor
25%
130-nm albumin-bound paclitaxel
25%
Polyps
25%
telaprevir
24%
Physicians' Practice Patterns
24%
Colorectal Surgery
24%
Drug Approval
24%
Randomized Controlled Trials
23%
Hepatitis E
23%
Leucovorin
22%
Chemical and Drug Induced Liver Injury
21%
Adjuvant Chemotherapy
21%
Esophagogastric Junction
21%
Chemoradiotherapy
21%
Erlotinib Hydrochloride
20%
Celecoxib
20%
Enteritis
20%